Compare KEP & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | KEP | ABVX |
|---|---|---|
| Founded | 1961 | 2013 |
| Country | South Korea | France |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | |
| Sector | Utilities | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.5B | 11.9B |
| IPO Year | 1996 | 2022 |
| Metric | KEP | ABVX |
|---|---|---|
| Price | $12.00 | $114.04 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $131.31 |
| AVG Volume (30 Days) | ★ 914.9K | 800.9K |
| Earning Date | 06-16-2026 | 03-23-2026 |
| Dividend Yield | ★ 2.82% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.18 | $52.14 |
| Revenue Next Year | $2.21 | $4,132.27 |
| P/E Ratio | $4.54 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.16 | $69.81 |
| 52 Week High | $23.41 | $148.83 |
| Indicator | KEP | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 53.65 | 43.20 |
| Support Level | $11.81 | $107.67 |
| Resistance Level | $12.48 | $129.00 |
| Average True Range (ATR) | 0.19 | 3.63 |
| MACD | 0.04 | -0.48 |
| Stochastic Oscillator | 67.57 | 33.75 |
Korea Electric Power Corp is an electric utility company in which the government of South Korea holds a controlling stake. The firm operates in the following segments: Transmission and distribution, Electric power generation (Nuclear), Electric power generation (Non-Nuclear), Plant maintenance & engineering service, and Others. The majority of the energy produced by the company comes from its nuclear and coal-fired assets. Korea Electric Power generates revenue through the Transmission and distribution segment. Geographically, it derives maximum revenue from Domestic operations.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.